Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 25, 2015, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,500.00 to $440,121,045.60.

Highlighted Stocks Traded by Insiders:

Cardiovascular Systems (CSII) - FREE Research Report

Kenny Kevin J, who is Exec. VP, Sales & Mtkg at Cardiovascular Systems, sold 3,833 shares at $35.51 on Feb. 25, 2015. Following this transaction, the Exec. VP, Sales & Mtkg owned 68,903 shares meaning that the stake was reduced by 5.27% with the 3,833-share transaction.

The shares most recently traded at $38.74, up $3.23, or 8.33% since the insider transaction. Historical insider transactions for Cardiovascular Systems go as follows:

  • 4-Week # shares sold: 38,248
  • 12-Week # shares sold: 38,248
  • 24-Week # shares bought: 10,250
  • 24-Week # shares sold: 44,933

The average volume for Cardiovascular Systems has been 229,400 shares per day over the past 30 days. Cardiovascular Systems has a market cap of $1.2 billion and is part of the health care sector and health services industry. Shares are up 24.53% year-to-date as of the close of trading on Wednesday.

Cardiovascular Systems, Inc., a medical device company, focuses on developing and commercializing minimally invasive treatment solutions for vascular diseases. Currently, there are 7 analysts who rate Cardiovascular Systems a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CSII - FREE

TheStreet Quant Ratings rates Cardiovascular Systems as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full Cardiovascular Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

General Motors (GM) - FREE Research Report

Ardila Jaime, who is Executive Vice President at General Motors, sold 2,953 shares at $37.58 on Feb. 25, 2015. Following this transaction, the Executive Vice President owned 26,532 shares meaning that the stake was reduced by 10.02% with the 2,953-share transaction.

The shares most recently traded at $37.88, up $0.30, or 0.79% since the insider transaction. Historical insider transactions for General Motors go as follows:

  • 4-Week # shares sold: 18,284
  • 12-Week # shares sold: 18,284
  • 24-Week # shares sold: 18,284

The average volume for General Motors has been 15.7 million shares per day over the past 30 days. General Motors has a market cap of $60.8 billion and is part of the consumer goods sector and automotive industry. Shares are up 8.45% year-to-date as of the close of trading on Wednesday.

General Motors Company designs, builds, and sells cars, crossovers, trucks, and automobile parts worldwide. It operates through GM North America, GM Europe, GM International Operations, GM South America, and GM Financial segments. The stock currently has a dividend yield of 3.18%. The company has a P/E ratio of 22.9. Currently, there are 8 analysts who rate General Motors a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GM - FREE

TheStreet Quant Ratings rates General Motors as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full General Motors Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hydrogenics (HYGS) - FREE Research Report

CommScope, Inc. of North Carolina, who is 10% Owner at Hydrogenics, sold 9,094 shares at $14.27 on Feb. 25, 2015. Following this transaction, the 10% Owner owned 1.4 million shares meaning that the stake was reduced by 0.64% with the 9,094-share transaction.

The shares most recently traded at $14.17, down $0.10, or 0.7% since the insider transaction. Historical insider transactions for Hydrogenics go as follows:

  • 4-Week # shares sold: 91,663
  • 12-Week # shares sold: 112,363
  • 24-Week # shares sold: 194,363

The average volume for Hydrogenics has been 88,500 shares per day over the past 30 days. Hydrogenics has a market cap of $143.1 million and is part of the industrial goods sector and industrial industry. Shares are up 8.58% year-to-date as of the close of trading on Wednesday.

Hydrogenics Corporation, together with its subsidiaries, designs, develops, and manufactures hydrogen generation products based on water electrolysis technology; and fuel cell products based on proton exchange membrane technology. Currently, there are 2 analysts who rate Hydrogenics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HYGS - FREE

TheStreet Quant Ratings rates Hydrogenics as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Hydrogenics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null